Catalog No.
PAB86901
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Cetuximab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Erbitux.
Specificity
The product is specific for Cetuximab. This antibody serves as an excellent positive control for Cetuximab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 205923-56-4
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Cetuximab (Erbitux) is a chimeric (mouse/human) monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab, as an epidermal growth factor receptor (EGFR) inhibitor, binds to EGFR.
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC., PMID:40511820
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection., PMID:40503012
Epidermal Growth Factor Receptor (EGFR) Downregulation by Cetuximab in Salivary Duct Carcinoma: A Case Report., PMID:40486390
Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples., PMID:40467730
First-line treatment with a combination of immunotherapy, anti-EGFR monoclonal antibodies, and chemotherapeutics for unresectable left KRAS/BRAF wild-type microsatellite-stable colorectal cancer: a case report., PMID:40460045
Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy., PMID:40455297
A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models., PMID:40452841
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma., PMID:40448574
[Research progress on the mechanisms of resistance to cetuximab targeted therapy in head and neck squamous cell carcinoma]., PMID:40443385
Evaluation of real-time pharmacokinetics using fluorescence imaging system in Near-infrared photoimmunotherapy for head and neck cancer., PMID:40424829
Mitochondrial damage and reactive oxygen species production in C. elegans: key factors in CdTe/ZnS quantum dot-Cet probes., PMID:40421499
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia., PMID:40417835
miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer., PMID:40414859
The Role of Monoclonal Antibodies as Therapeutics in HPV-Related Head and Neck Cancers: An Updated Review., PMID:40407689
Antibody Labeling With FITC Facilitates Controlled Release From Peptide Hydrogels Bearing Fc-Binding Motifs., PMID:40400208
A platform for SpyCatcher conjugation to native antibodies., PMID:40386161
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy., PMID:40383966
First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis., PMID:40378108
Evaluation of the usefulness of protocol-based magnesium supplementation for hypomagnesemia in patients with advanced or recurrent colorectal cancer treated with panitumumab., PMID:40366467
Employing the SpyTag-SpyCatcher Reaction for the Modification of Supramolecular Polymers with Functional Proteins., PMID:40365870
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer., PMID:40346041
Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer., PMID:40340861
Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR., PMID:40334314
Experimental System Design and Modelling of EGFR Extracellular Domain and Its Mutant Binding to Antibody Interacting Partner., PMID:40332084
Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges., PMID:40329596
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial., PMID:40328753
Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer., PMID:40327456
Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC., PMID:40323213
ADCC: the rock band led by therapeutic antibodies, tumor and immune cells., PMID:40308580
Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312., PMID:40304209
Development of Multifunctional Targeted Dual-Loaded Polymeric Nanoparticles for Triple-Negative Breast Cancer Treatment., PMID:40284424
Associations between early tumor shrinkage/depth of response and survival from the ARCAD database., PMID:40280867
Bioorthogonal Reaction of o-Quinone with Furan-2(3H)-One for Site-Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes., PMID:40278820
Uncovering cell cycle-dependent effects on cell survival in near-infrared photoimmunotherapy., PMID:40273966
Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison., PMID:40272712
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study., PMID:40262400
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy., PMID:40252510
Thermosensitive chitosan hydrogel loaded cetuximab: a novel approach for parenteral controlled delivery., PMID:40237790
A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux®) in Healthy Chinese Male Subjects., PMID:40232626
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer., PMID:40222201
Retrospective multicentric survival analysis of patients receiving TPEx regimen as first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma., PMID:40220661
Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials., PMID:40215447
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306., PMID:40179821
Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study., PMID:40163686
Enhancing activity of FcαRI-bispecific antibodies using glycoengineering., PMID:40156381
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial., PMID:40154210
Microenvironment-based immunotherapy in oral cancer: a comprehensive review., PMID:40153139
Cetuximab and Paclitaxel Drug Response in Head and Neck Tumor Stem Cells., PMID:40149887
Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal Cancer., PMID:40141198
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors., PMID:40140179
For research use only. Not for human or drug use.
